What is this study trying to find out about retained products of conception?

This study is evaluating whether conservative treatment can help naturally resolve retained products of conception when combined with enhanced myometrial vascularity. It aims to understand the effects of treatments like mifepristone or expectant management. The research is led by Fu Xing Hospital, Capital Medical University, to improve care options for women after miscarriage or delivery.

Who may be eligible for this retained products of conception clinical trial?

Women who have had a miscarriage or delivery within the past 8 weeks and are willing to try conservative management may be eligible. Participants must be hemodynamically stable and able to provide informed consent. The study excludes those with heavy bleeding or active infections. Please review eligibility criteria for more details.

Is there any cost to participate in this retained products of conception clinical trial?

Study-related care, including the study treatment and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel or related costs.

Actively Recruiting

FEMALE

ID06862089

Observational Study on Conservative Treatment Effects for Retained Products of Conception and Enhanced Myometrial Vascularity

Led by Fu Xing Hospital, Capital Medical University · Updated on 2025-06-15

120

Participants Needed

Research Sites

8 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are investigating the effects of conservative treatment on people with retained products of conception RPOC and enhanced myometrial vascularity EMV following miscarriage or delivery. The study aims to determine whether natural resolution of RPOC can be achieved by combining it with EMV through conservative methods. This observational study is led by Fu Xing Hospital, Capital Medical University, and focuses on evaluating therapeutic outcomes after two menstrual cycles. Participants will receive conservative treatments such as mifepristone, GnRH-a, or expectant management after being diagnosed with RPOC and EMV. The main treatment period spans two menstrual cycles, after which therapeutic effects will be assessed. No additional interventions or comparison groups are mentioned, as this is an observational study monitoring natural and treatment-influenced resolution. During the study, participants will undergo transvaginal ultrasound at the end of the second menstrual cycle to check for resolution of RPOC. Researchers will also measure the disappearance rate of EMV immediately after completing conservative treatment. The study will track participants response to treatment and monitor their health status, with a focus on treatment efficacy and safety throughout the observation period ending in late 2026.

CONDITIONS

Brief Title

A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV

Who Can Participate

FEMALE

Eligibility Criteria

You may qualify if you...

Recent history of miscarriage or delivery within the past 8 weeks
Strong willingness to undergo conservative management
Hemodynamically stable
Signed informed consent form

You will not qualify if you...

Heavy vaginal bleeding requiring immediate surgical intervention
Active pelvic or systemic infection (e.g., fever over 38°C, elevated CRP or WBC)
Severe dysfunction of heart, liver, or kidney
Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)
Suspected ectopic pregnancy or gestational trophoblastic disease confirmed by ultrasound or beta-hCG levels
Placenta accreta spectrum disorders diagnosed during current pregnancy
History of uterine artery embolization

Research Team

Rui Huang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here